Robert W. Baird Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price

Spyre Therapeutics (NASDAQ:SYRE) had its price target boosted by Robert W. Baird from $65.00 to $90.00 in a research note released on Tuesday morning, MarketBeat reports. Robert W. Baird currently has an outperform rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Wells Fargo & Company raised their target price on shares of Spyre Therapeutics from $50.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday. Raymond James Financial started coverage on shares of Spyre Therapeutics in a research note on Monday. They set a “strong-buy” rating and a $80.00 target price on the stock. Wall Street Zen cut shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Citigroup started coverage on shares of Spyre Therapeutics in a research note on Wednesday, December 17th. They issued a “buy” rating and a $64.00 price objective on the stock. Finally, Stifel Nicolaus lifted their price objective on shares of Spyre Therapeutics from $70.00 to $92.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $82.50.

Spyre Therapeutics Stock Performance

Spyre Therapeutics stock opened at $64.01 on Tuesday. The firm’s 50-day moving average is $43.04 and its 200-day moving average is $33.08. Spyre Therapeutics has a 1 year low of $12.04 and a 1 year high of $75.00. The company has a market cap of $5.04 billion, a P/E ratio of -30.77 and a beta of 2.93.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). As a group, sell-side analysts predict that Spyre Therapeutics will post -4.46 earnings per share for the current year.

Insider Transactions at Spyre Therapeutics

In other news, insider Sheldon Sloan sold 7,958 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $50.00, for a total value of $397,900.00. Following the completion of the sale, the insider directly owned 7,958 shares in the company, valued at approximately $397,900. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 7,500 shares of the business’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $49.34, for a total transaction of $370,050.00. Following the completion of the sale, the chief financial officer owned 97,994 shares of the company’s stock, valued at $4,835,023.96. The trade was a 7.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 62,958 shares of company stock worth $2,734,375. 6.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Spyre Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SYRE. Perceptive Advisors LLC increased its position in Spyre Therapeutics by 149.6% during the fourth quarter. Perceptive Advisors LLC now owns 3,069,225 shares of the company’s stock worth $100,548,000 after acquiring an additional 1,839,780 shares during the period. Janus Henderson Group PLC increased its position in Spyre Therapeutics by 13,969.3% during the fourth quarter. Janus Henderson Group PLC now owns 1,829,009 shares of the company’s stock worth $59,918,000 after acquiring an additional 1,816,009 shares during the period. RA Capital Management L.P. bought a new position in Spyre Therapeutics during the fourth quarter worth $53,124,000. Remedium Capital Partners LLC bought a new position in Spyre Therapeutics during the fourth quarter worth $47,706,000. Finally, TCG Crossover Management LLC bought a new position in Spyre Therapeutics during the third quarter worth $18,446,000. Institutional investors own 80.39% of the company’s stock.

Key Headlines Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Top-line SPY001 Part A (SKYLINE) Phase 2 induction data show rapid, deep efficacy and a clean safety profile — 9.2‑point RHI reduction, ~40% clinical remission and ~51% endoscopic improvement at 12 weeks, claims best‑in‑class potential. Reuters: Spyre’s inflammatory bowel drug shown to reduce disease activity in mid-stage study
• Positive Sentiment: Company press release highlights statistically significant primary endpoint and frames SPY001 as “potential best‑in‑class,” underpinning upside for commercial and combination-regimen value. GlobeNewswire: SPY001 Part A Induction Results
• Positive Sentiment: Multiple sell‑side firms raised targets and ratings after the data: Leerink to $106 (Outperform), BTIG to $98 (Buy), and Robert W. Baird to $90 (Outperform) — these upgrades increase upside expectations and buy‑side interest. Benzinga: Analyst Price Target Raises
• Positive Sentiment: Analyst/market commentary (Seeking Alpha) frames the SPY001 dataset as a catalyst-rich setup for 2026 with valuation implying high expectations for mono and combination uses. Seeking Alpha: Strong SPY001 Data
• Neutral Sentiment: Trading was briefly halted early on the news (“news pending”), a common step around material corporate/clinical announcements; the halt has ended and normal trading resumed. Trading Halt Notice
• Negative Sentiment: Spyre launched an underwritten public offering to raise $300M of common stock (with a 30‑day option for an additional $45M), which creates near‑term dilution risk and may pressure the share price. GlobeNewswire: Proposed Public Offering
• Negative Sentiment: Market reaction was mixed: coverage notes an immediate sell‑off tied to the offering announcement, reflecting investor sensitivity to dilution despite the strong clinical readout. Investing.com: Stock Falls on $300M Offering

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.